von Krusenstiern, A. Nikolai
Robson, Ryan N. http://orcid.org/0000-0003-2524-5277
Qian, Naixin
Qiu, Baiyu
Hu, Fanghao http://orcid.org/0000-0002-8659-4027
Reznik, Eduard
Smith, Nailah http://orcid.org/0000-0002-2402-6470
Zandkarimi, Fereshteh
Estes, Verna M.
Dupont, Marcel
Hirschhorn, Tal
Shchepinov, Mikhail S.
Min, Wei http://orcid.org/0000-0003-2570-3557
Woerpel, K. A. http://orcid.org/0000-0002-8515-0301
Stockwell, Brent R. http://orcid.org/0000-0002-3532-3868
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (F30AG066272)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (EB029523)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM118730)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P01CA87497, R35CA209896)
Article History
Received: 9 January 2022
Accepted: 21 December 2022
First Online: 6 February 2023
Competing interests
: B.R.S. is an inventor on patents and patent applications involving ferroptosis; co-founded and serves as a consultant to ProJenX, Inc. and Exarta Therapeutics; holds equity in Sonata Therapeutics; serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP; and receives sponsored research support from Sumitomo Dainippon Pharma Oncology. M.S.S. is the Chief Scientific Officer of Retrotrope, Inc. The remaining authors declare no competing interests.